ATE324106T1 - Zusammensetzungen und verfahren zur regulierung des serumcholesterins - Google Patents
Zusammensetzungen und verfahren zur regulierung des serumcholesterinsInfo
- Publication number
- ATE324106T1 ATE324106T1 AT00910316T AT00910316T ATE324106T1 AT E324106 T1 ATE324106 T1 AT E324106T1 AT 00910316 T AT00910316 T AT 00910316T AT 00910316 T AT00910316 T AT 00910316T AT E324106 T1 ATE324106 T1 AT E324106T1
- Authority
- AT
- Austria
- Prior art keywords
- serum cholesterol
- identified
- methods
- drugs
- compositions
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title 1
- 229940113549 Cholesterol inhibitor Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000003524 antilipemic agent Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 102000000853 LDL receptors Human genes 0.000 abstract 1
- 108010001831 LDL receptors Proteins 0.000 abstract 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 abstract 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003408 sphingolipids Chemical class 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04003—Phospholipase C (3.1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22056—Caspase-3 (3.4.22.56)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Virology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12144799P | 1999-02-24 | 1999-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE324106T1 true ATE324106T1 (de) | 2006-05-15 |
Family
ID=22396797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00910316T ATE324106T1 (de) | 1999-02-24 | 2000-02-23 | Zusammensetzungen und verfahren zur regulierung des serumcholesterins |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1155121B1 (de) |
| JP (1) | JP2002537407A (de) |
| AT (1) | ATE324106T1 (de) |
| AU (1) | AU776785B2 (de) |
| CA (1) | CA2362549A1 (de) |
| DE (1) | DE60027551T2 (de) |
| ES (1) | ES2261187T3 (de) |
| WO (1) | WO2000050574A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984645B2 (en) | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| WO2004064820A2 (en) * | 2003-01-20 | 2004-08-05 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
| NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
| US7371759B2 (en) | 2003-09-25 | 2008-05-13 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| JP5154218B2 (ja) * | 2004-03-16 | 2013-02-27 | ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法 |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| EP1618876A1 (de) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Verwendung von Sphingolipiden zur Vorbeugung und Behandlung von Atherosklerose |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| ATE539741T1 (de) | 2004-11-30 | 2012-01-15 | Tno | Sphingolipide bei der behandlung und prävention von hepatischer steatose |
| EP1661562A1 (de) * | 2004-11-30 | 2006-05-31 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Verwendung von Sphingolipiden zur Behandlung und Vorbeugung von Steatose |
| WO2006076597A1 (en) | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| US7314882B2 (en) | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| US7361766B2 (en) | 2005-01-12 | 2008-04-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| WO2006078697A1 (en) | 2005-01-18 | 2006-07-27 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
| WO2006086464A2 (en) | 2005-02-10 | 2006-08-17 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5ht modulators |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| TW200726765A (en) | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| EP1898922A4 (de) * | 2005-07-04 | 2012-03-14 | Ramu Krishnan | Verbessertes arzneimittel oder pharmazeutische verbindungen und eine zubereitung davon |
| US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| EP1923060A1 (de) * | 2006-11-08 | 2008-05-21 | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO | Zusammensetzungen von einem Sphingolipiden und einem HMG-CoA-Reduktase-Hemmer zur Behandlung von Hypercholesterämie |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| DE102007051338A1 (de) * | 2007-10-26 | 2009-04-30 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien |
| PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
| CA2756786A1 (en) | 2009-03-27 | 2010-09-30 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
| EP2892897A1 (de) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1 |
| WO2014039411A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
| WO2020016335A1 (en) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876789A (en) * | 1972-03-31 | 1975-04-08 | American Home Prod | (2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides, as anti-lipemic agents |
| US5498696A (en) * | 1993-05-13 | 1996-03-12 | Board Of Regents, The University Of Texas System | Sterol regulatory element binding proteins and their use in screening assays |
| FR2747307B1 (fr) * | 1996-04-11 | 1998-07-10 | Ravi Shrivastava | Application a titre de medicament des ceramides et compositions notamment pharmaceutiques les renfermant |
-
2000
- 2000-02-23 WO PCT/US2000/004657 patent/WO2000050574A1/en not_active Ceased
- 2000-02-23 EP EP00910316A patent/EP1155121B1/de not_active Expired - Lifetime
- 2000-02-23 CA CA002362549A patent/CA2362549A1/en not_active Abandoned
- 2000-02-23 JP JP2000601138A patent/JP2002537407A/ja active Pending
- 2000-02-23 ES ES00910316T patent/ES2261187T3/es not_active Expired - Lifetime
- 2000-02-23 AU AU32429/00A patent/AU776785B2/en not_active Ceased
- 2000-02-23 AT AT00910316T patent/ATE324106T1/de not_active IP Right Cessation
- 2000-02-23 DE DE60027551T patent/DE60027551T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2261187T3 (es) | 2006-11-16 |
| EP1155121B1 (de) | 2006-04-26 |
| WO2000050574A1 (en) | 2000-08-31 |
| AU776785B2 (en) | 2004-09-23 |
| CA2362549A1 (en) | 2000-08-31 |
| EP1155121A1 (de) | 2001-11-21 |
| DE60027551D1 (de) | 2006-06-01 |
| JP2002537407A (ja) | 2002-11-05 |
| DE60027551T2 (de) | 2007-05-10 |
| AU3242900A (en) | 2000-09-14 |
| EP1155121A4 (de) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE324106T1 (de) | Zusammensetzungen und verfahren zur regulierung des serumcholesterins | |
| ATE364696T1 (de) | Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts | |
| ATE427499T1 (de) | Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| WO2003103581A3 (en) | Compositions and methods for liver growth and liver protection | |
| EP1402067A4 (de) | Hs2sts als modifikatoren des p53-wegs und verwendungsverfahren | |
| ATE269295T1 (de) | Btk inhibitoren und verfahren zur identifizierung und verwendung | |
| DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
| DE69936948D1 (de) | Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten | |
| BR0317896A (pt) | Complexos de cristais de proteìna e polìmeros iÈnicos | |
| BR0200923A (pt) | Composições que contêm produtos derivados de leguminosas | |
| DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
| ATE448775T1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| SE8902532D0 (sv) | Bestaemning av plasmaproteiner | |
| DE60323592D1 (de) | Verfahren zur Identifizierung von Agenzien zur Behandlung von Anfällen, neurologischen Erkrankungen, Endokrinopathien und hormonalen Erkrankungen | |
| EP1109548A4 (de) | Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole | |
| ATE394124T1 (de) | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums | |
| DE69840752D1 (de) | Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE356995T1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| ATE242008T1 (de) | Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen | |
| DE69838667D1 (de) | Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |